The Online Investor

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Wed., Feb. 26, 6:28 PM

Slide #35. Meridian Bioscience, Inc. Exalenz Bioscience Ltd.

Acquirer: Meridian Bioscience, Inc. (NASDAQ:VIVO)
Acquiree: Exalenz Bioscience Ltd.
Details: Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for 6.10 per share in cash with an implied transaction value of approximately $49 million. The agreement has been approved unanimously by the boards of directors of both companies.

Meridian Bioscience is a life science company with principal businesses in the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by IVD manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. Co.'s reportable segments are: Diagnostics, which products span a menu of testing platforms and technologies; and Life Science.

VIVO SEC Filing Email Alerts Service


Open the VIVO Page at The Online Investor »

Company Name: 
Meridian Bioscience Inc.
Website: 
www.meridianbioscience.com
Sector: 
Medical Instruments & Supplies
Number of ETFs Holding VIVO: 
34
Total Market Value Held by ETFs: 
$69.87M
Total Market Capitalization: 
$334.00M
% of Market Cap. Held by ETFs: 
20.92%
 

Open the VIVO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Sell (1.33 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.